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a b s t r a c t
Introduction: Radiation therapy is crucial to effective cancer treatment. Modern treatment strategies have
reduced possible skin injury, but few clinical studies have addressed the dose relationship between radi-
ation exposure and skin reaction. This prospective clinical study analyzes skin oxygenation/perfusion in
patients undergoing fractionated breast conserving therapy via hyperspectral imaging (HSI).
Methods: Forty-three women undergoing breast conserving therapy were enrolled in this study. Optically
stimulated luminescent dosimeters (OSLDs) measured radiation exposure in four sites: treatment breast,
lumpectomy scar, medial tattoo and the control breast. The oxygenation/perfusion states of these sites
were prospectively imaged before and after each treatment fraction with HSI. Visual skin reactions were
classified according to the RTOG system.
Results: 2753 observations were obtained and indicated a dose-response relationship between radiation
exposure and oxygenated hemoglobin (OxyHb) after a 600 cGy cumulative dose threshold. There was a
relatively weak association between DeoxyHb and radiation exposure. Results suggest strong correlations
between changes in mean OxyHb and skin reaction as well as between radiation exposure and changes in
skin reaction.
Conclusion: HSI demonstrates promise in the assessment of skin dose as well as an objective measure of
skin reaction. The ability to easily identify adverse skin reactions and to modify the treatment plan may
circumvent the need for detrimental treatment breaks.
 2017 The Authors. Published by Elsevier Ireland Ltd on behalf of European Society for Radiotherapy and
Oncology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
Introduction
Radiation therapy remains a critically important and valuable
component for oncologic patient care. Modern equipment and
refined treatment algorithms have improved normal tissue effects
from treatment particularly in breast. However, the use of
increased radiation dose to tumor targets and compressed radia-
tion treatment fractionation schedules still lead to significant
ischemic effects of radiation therapy on dermal circulation and
subcutaneous tissue in other parts of the body. It is still unclear
whether or not there is a dose–response relationship between radi-
ation to both skin oxygenation and adverse skin reactions. Further-
more, from a surgical perspective, since reconstruction often
requires operating within irradiated tissue, better understanding
the underlying changes in skin microcirculation is paramount.
Encouraging earlier clinical studies demonstrated that laser
Doppler flowmetry (LDF) could be used to study acute changes in
cutaneous microvasculature [1,2], but LDF is based on the capillary
flow velocity and may not be reflective of physiological tissue oxy-
genation. Our lab has focused on hyperspectral imaging (HSI) for
evaluation of skin oxygenation and perfusion after a variety of inju-
ries. HSI derived oxygenation has been shown to correlate with
transcutaneous PO2 measurements as well as intravascular volume
http://dx.doi.org/10.1016/j.ctro.2017.03.003
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[3–5]. We have utilized a commercially produced HSI device,
which provides near real-time analysis of oxygenated and deoxy-
genated hemoglobin (OxyHb and DeoxyHb, respectively) content
in skin. In previous animal studies, we successfully demonstrated
that this technology reliably detects and assesses skin changes
after exposure to both ionizing and thermal radiation [6–8]. Our
translational studies on the acute phase suggest that cutaneous
changes in oxygenation may be dose related and that this may
be a potential surrogate marker for radiation exposure [9]. Subse-
quent studies by other investigators have used similar spectro-
scopic techniques and validated dose related oxygenation
changes [10,11]. However, these previous studies have all been
based on single fraction exposures of radiation and therefore have
limited external validity to clinical fractionated radiation
schedules.
In this prospective clinical study, we utilize fractionated dose
therapy in breast cancer patients undergoing breast conserving
therapy (BCT) radiation as a model for radiation exposure. By mea-
suring their received dose at the skin level and assessing their skin
oxygenation at those sites using our previous HSI methodology, we
evaluate any correlation between dose and skin oxygenation level
in the acute treatment phase. We designed this study around
breast cancer patients since their standardized treatment maps
provide consistent sites for comparison. Based on our previous
studies, we hypothesize that breast skin OxyHb level will rise dur-
ing the period of irradiation.
Methods
Under IRB approved protocol, all patients (n = 43) were
recruited from the Radiation Oncology Clinic at the University
Campus of UMass Memorial Healthcare Center. Women aged 18–
85 who were planning on having breast radiation as part of breast
conserving therapy (i.e. lumpectomy plus radiation) and were able
to provide informed consent were invited to participate in the
study. However, patients with previous breast irradiation in situa-
tions where radiation therapy prescription doses may be altered
(excluding boost dosage), inflammatory skin diseases (e.g. psoria-
sis, eczema) over the breast area to be irradiated, and collagen vas-
cular disease and/or other systemic vasculitides were excluded
from the study. Additionally, patients who were unable to sit or
lie down comfortably for 20 s for image acquisition were excluded.
Clinical information including patient age, BMI, smoking status,
significant past medical history, and history of chemotherapy were
recorded. All patients were enrolled and consented to the study
either by their radiation oncologist or the study coordinator.
Radiation measurement
Breast irradiation for breast conserving therapy involved two
opposing X-ray beams from a megavoltage medical linear acceler-
ator. Radiation dose measurements at the skin surface were
assessed by use of optically stimulated luminescent dosimeters
(OSLD). Calibrated OSLDs were placed on each patient’s chest in
four areas during the initial treatment fraction. Three measured
areas were in the irradiated field: middle of treatment breast
(TB), lumpectomy scar site (SCAR), and medial tattoo (MT). TB
and SCAR sites were selected since they were always within the
irradiated field. MT was chosen as a readily identifiable site in each
patient that could demonstrate a dose gradient as it is offset from
the target site. One OSLD was placed on the nipple of the untreated
breast as control (CONTROL). (Fig. 1) All subsequent fractions were
assumed to have the same skin dose, unless a boost was noted. In
this case, an additional OSLD was placed and measured that ses-
sion’s additional doses. Each OSLD was developed and read 24 h
after radiation exposure. Cumulative dose measurements were cal-
culated for each treatment site as number of treatment fractions
times OSLDmeasurement, with additions accounting for any boost.
Hyperspectral imaging
Our group has previously established the use of monitoring of
irradiated skin using HSI [8,9]. A commercial FDA-approved hyper-
spectral device (OxyVu-2TM (Hypermed, Inc., Waltham, MA)) was
used to obtain images at each OSLD measurement site (TB, SCAR,
MT and CONTROL) at baseline before therapy as well as before
and after each treatment fraction. The OxyVu-2TM analyzes the skin
content of oxygenated and deoxygenated hgb at a depth of 2 mm,
which corresponds anatomically to the subdermal plexus. The sys-
temwas calibrated to a reference card for all acquisitions, and pixel
reflectance was determined relative to this standard reflectance. A
target dot was used to correct for motion artifact from respiratory
effort. Patients were asked to position themselves prone on
stretcher during the imaging. Spatial maps of tissue oxygenation
were then generated using the device’s proprietary algorithms.
The general optical properties of this device have been previously
described [12]. A narrow band-pass, liquid–crystal tunable filter
(LCTF-10-20, CRI, Inc. Hopkinton, Massachusetts) was used to vary
the wavelength of light passed on to a digital imaging detector
(Guppy F-146B, Allied Vision Technologies, Stadtroda, Germany)
to provide many images at 15 select wavelengths between 500
and 660 nm. Broadband light-emitting diodes were used to illumi-
nate the sample (LUXEON, Philips Lumiled, Inc. San Jose, Califor-
nia). Twenty-second scans of tissue samples were obtained at
approximately a 17-inch focal distance. Color images were created
from the scans to demonstrate tissue oxygenation spatially. The
spatial resolution of the OxyHb and DeoxyHb images was 60 lm.
Skin reaction assessment
At each HSI acquisition, a concurrent digital photograph was
obtained of each measured site. These photographs were graded
by two independent technicians using the RTOG skin toxicity scale
on a categorical scale of 0 through 4 (0 = no reaction, 1 = slight ery-
thema, 2 = bright erythema or patchy desquamation, 3 = confluent
desquamation, or 4 = ulceration) [13]. The average grading score
between the two technicians was used for analysis. Due to a com-
puter hard drive failure there were 10 women with lost data for at
least one skin reading; in this case the single technician’s reading
was used in lieu of a mean.
Statistical methods
We examined the unadjusted dose-OxyHb association by com-
puting mean change in OxyHb in each successive cumulative dose
interval, in 200 cGy dose increments. We computed the linear
slope as cumulative dose increased (adjusted for woman), to help
assess the general shape of association, and to identify at what
cumulative dose the association becomes detectable.
We used a mixed model, in which individual woman was trea-
ted as a random effect, to examine the association between cumu-
lative radiation dose and change from baseline OxyHb or DeoxyHb
at skin surface. Cumulative radiation dose was the cumulative sum
of each day’s dose, including any boost doses. Changes in hemoglo-
bin were differences between measurements immediately after a
daily dose, and baseline hemoglobin before treatment, where each
woman had a different baseline at each location (TB, SCAR, MT, and
CONTROL, where CONTROL received minimal or insignificant
radiation).
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The method of fractional polynomials was used to examine pos-
sible non-linearity between dose and hemoglobin change [14].
Associations were assessed independently for each radiation loca-
tion. We tested for possible modifications to the dose-hemoglobin
associations by adding the following covariates to our final models,
one at a time: age, body mass index, Fitzpatrick score, and history
of chemotherapy, smoking, hypertension and type II diabetes.
Because the effect of cumulative dose might differ depending on
how rapidly it was attained, we included day since baseline in final
models, to help control for time (the dose-hemoglobin estimate
may then be interpreted as being at a random day since baseline).
Differences in dose-hemoglobin associations at the 3 main loca-
tions (TB, SCAR, and MT), were evaluated by comparing model like-
lihoods for models with additional terms for location-specific
estimates to models without the additional terms. To obtain a
sense of how much of the variation in OxyHb is due to cumulative
dose plus the individual woman, we computed coefficients of cor-
relation (R2) for final adjusted models by ordinary least squares
regression, treating individual woman as a fixed effect.
A two-sided a-level of 0.05 was used to determine statistical
significance and report confidence intervals. All analyses were con-
ducted using the SAS software package, version 9.3 (SAS Institute).
Categorical variables are shown as frequencies with proportions;
continuous variables are shown as means with minimum, maxi-
mum, and standard deviation.
Results
Our study sample consisted of 43 women of mean age 58 years
(range 42–82), mean BMI 29 kg/m2(range 20–46), mean Fitzpatrick
scale 2.6 units (range 1–5), 33% had a past history of chemother-
Fig. 1. (Above) Schematic of CONTROL (A), MT (B), SCAR (C) and TB (D) sites. Arrows indicate OSLD placement. (Below) Mean unit change since baseline in oxygenated and
deoxygenated hemoglobin by cumulative radiation interval (n = 1770 observations at scar and treatment breast).
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apy, 42% had past or current smoking, 28% were hypertensive, and
4.7% had type 2 diabetes (Table 1).
Relationship between radiation dose and change in hemoglobin
Forty-three women having 2753 observations at TB, SCAR, and
MT were included in analyses. Data from the control breast were
ignored, as radiation and changes in hemoglobin were minimal
there. Mean treatment time since baseline was approximately
16 days, with most treatments extending to approximately 31 days
with a maximum of 36 days.
For OxyHb response to dose changes, we analyzed 41 women
with data at MT, 36 at SCAR, and 43 at TB (Table 2). Eight observa-
tions with a total dose >5000 cGy were excluded, since there was
not enough information at such high doses to reach firm conclu-
sions. Observations below a dose level of 2 cGy for OxyHb were
also excluded, as the noise from the hyperspectral measurements
becomes dominant. The mean dose at scar and TB was approxi-
mately 2000 cGy, with maxima 4942 cGy and 4547 cGy respec-
tively. The mean dose at MT was approximately 1000 cGy with a
maximum of 3366 cGy. Mean changes in OxyHb since baseline
were larger and similar at SCAR and TB than at MT, and uniformly
larger than mean changes in DeoxyHb.
Unadjusted mean changes in OxyHb and DeoxyHb at successive
cumulative radiation dose intervals up to 4942 cGy, for 36 women
with a total of 1770 observations at SCAR (n = 868) and TB
(n = 902), appear in Table 3. For this analysis, we omitted 7 women
who had TB but no SCAR data, and MT because of its narrower dose
range. Linear slopes were estimated (adjusted for random woman)
between change in cumulative dose and change in hemoglobin,
where each interval extends from 0 cGy to the interval endpoint
(eg, for the interval 200–<400 cGy, the slope estimate includes
the 138 observations between 0 and <400 cGy). The cumulative
linear slope estimate becomes quite statistically significant
(p < 0.0001) between 600 and 800 cGy cumulative dose for OxyHb,
and between 2600 and 2800 cGy for DeoxyHb. The linear associa-
tion appears relatively weak for DeoxyHb, but strong and increas-
ing with higher dose for OxyHb to a maximum slope of 1.8 hgb
units per 100 cGy.
A plot of mean change in hemoglobin per cumulative radiation
interval to be linear for OxyHb; a lesser, possibly linear association
is seen for DeoxyHb (Fig. 1). We did not analyze DeoxyHb further
because of this relatively weak association.
Estimating a model based on SCAR and TB locations
The mixed model was used to examine the association between
cumulative radiation dose and change in OxyHb for the 36 women
with both SCAR and TB data, since the range of cumulative dose
was similar at each location.
The final model was of the form:
Change in oxygenated hgb since baseline = cum dose/100 cGy
+ (cum dose/100 cGy)0.5,
where cum dose is the cumulative radiation dose in cGy.
The first 2 terms were derived from the method of fractional
polynomials (p < 0.0001 vs linear cum dose). No other covariates
(see Statistical Methods) were statistically significant in the above
model, except for day of measurement (p = 0.0003). Models for
SCAR and TB had the same functional form (as above), and location
was not statistically significant (p = 0.09). Since SCAR and TB had
the same model form, we have 2 independent pieces of evidence
for the shape of association up to cumulative dose <5000 cGy.
In ordinary least squares regression, the R2 (% variation in
OxyHb explained by a covariate(s)) for a model containing cumu-
lative dose as specified above (and no other covariates) was 41%;
66% after adding woman as a fixed effect. For cumulative dose
modeled as a single linear term, R2 were 40% and 65%, respectively.
Comparable R2 for linear DeoxyHb were 6% (cumulative dose
alone) and 37% (adding patient).
Comparison of MT, SCAR, and TB locations using the final model
We refit mixed models for the 29 women who had information
at MT (448 observations), SCAR (445 observations), and TB (443
observations), to see if MT, with its lower cumulative dose, had a
similar association between OxyHb and dose as SCAR and TB;
and to compare the association found in the previous section for
SCAR and TB at their full dose range (Fig. 2) to the association at
a more restricted dose range, 383–2686 cGy. This range represents
the 5th percentile for SCAR and 95th percentile for MT dose,
respectively, ensuring a good degree of dose overlap at all 3
locations.
Best-fitting models were:
MT change in OxyHb = (cum dose/100 cGy)-0.5 + ln(cum
dose/100 cGy).
SCAR and TB change in OxyHb = (cum dose/100 cGy)2 + (cum
dose/100 cGy)2.
These models were statistically significantly better than a linear
cumulative dose association (p = 0.0005 for MT, p = 0.004 for SCAR
+ TB vs linear). SCAR and TB had similar non-linear individual asso-
ciations, although not of the same exact form; the form shown
above is for the 2 locations combined. When other covariates were
Table 1
Demographics and medical history (n = 43 women).
n (%)
Lumpectomy 42 (100)





























History of smoking 18 (42)
Vascular disease 12 (28)
Anemia 6 (14)
Hypertension 12 (28)
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added, they were not statistically significant, except for day of
measurement (p = 0.03 for MT and p = 0.03 for SCAR plus TB).
Fig. 2 shows the general shape of association between predicted
OxyHb and cumulative radiation dose at MT, and at SCAR and TB
combined, evaluated at 16 days after baseline. As with the broader
dose range for SCAR and TB (2–4942 cGy), the association is mainly
linear (700–2700 cGy), with some upward curvature for SCAR and
TB. Between 400 and 700 cGy the MT association is negative, the
SCAR plus TB association positive.
Comparison of skin reactions to dose and hemoglobin changes
Skin reactions during treatment from 2531 scans of 42 women
were evaluated by two independent study technicians. Due to lost
data, however, there were 29 scans with only one skin reaction
score recorded. Among this subset of 2502, complete agreement
in assessed skin reaction category was 68% between the 2 techni-
cians (radiation therapists); 0.6% differed by >1 category. Including
all scans for which there was at least one reading recorded there
were a total of 2531 readings: 27% were 0 to <1, 61% were 1 to
<2, 11% were 2 to <3, and 1% were 3 or higher. There was a strong
correlation between cumulative radiation dose and severity of skin
reaction at each of the measurement sites (Fig. 3). SCAR and TB
sites have similar mean cumulative doses for a given skin reaction,
with overlapping confidence intervals, while MT sites have smaller
mean doses for a given skin reaction.
Additionally, there was a strong correlation between change in
mean OxyHb and skin reaction (Fig. 3). Mean increases are seen
from skin reactions Null to 1 to 2, with a smaller increase from 2
to 3 and overlapping confidence intervals. As with cumulative
dose, mean change in OxyHb was similar at SCAR and TB, for a
given skin reaction.
Discussion
Despite the longstanding use of radiation therapy, there have
not been any definitive clinical studies which demonstrate the
relationships between skin dose, oxygenation, and adverse skin
Table 2
Summary of cumulative radiation dose and changes in hemoglobin (hgb), by treatment location.
Location # of observations Minimum Maximum Median Mean
Medial tattoo (41 women):
Cumulative dose, cGy 828 23 3366 798 1013
Change in oxygenated hgb, units 828 2 141 16 25
Change in deoxygenated hgb, units 828 26 316 2 3.3
Scar (36 women):
Cumulative dose, cGy 868 125 4942 2044 2073
Change in oxygenated hgb, units 868 2 158 32 40
Change in deoxygenated hgb, units 868 36 124 5 7.0
Treatment breast (43 women):
Cumulative dose, cGy 1057 8.6 4547 1945 1967
Change in oxygenated hgb, units 1057 2 176 32 40
Change in deoxygenated hgb, units 1057 51 78 3 2.6
Table 3
Unadjusted mean changes since baseline in oxygenated and deoxygenated surface blood hemoglobin, at increasing cumulative radiation dose interval, and cumulative linear
slopes (36 women with 1770 observations at scar and treatment breast).
N Median since baseline Days Cum dose Mean Oxy hgb Cum linear slope* (p-value) Mean Deoxy hgb Cum linear slope* (p)
53 7 days 0–<200 cGy 16.8 units 1.31 units (.67) .43 units 2.54 units (.20)
85 2 200–<400 14.5 1.31 (.20) 1.5 1.33 (.04)
82 4 400–<600 13.8 0.64 (.19) 2.3 0.59 (.11)
81 5 600–<800 18.9 1.17 (**) 1.7 0.39 (.08)
92 7 800–<1000 22.2 1.50 (**) 1.4 0.15 (.33)
99 9 1000–<1200 21.8 1.26 (**) 2.5 0.22 (.05)
95 10 12001400 27.3 1.40 (**) 3.6 0.23 (.01)
100 12 1400–<1600 28.0 1.35 (**) 2.1 0.17 (.02)
98 13 1600–<1800 30.6 1.32 (**) 2.8 0.14 (.02)
99 15 1800–<2000 32.0 1.29 (**) 4.3 0.20 (.0002)
102 16 2000–<2200 36.0 1.32 (**) 2.8 0.17 (.0003)
93 18 2200–<2400 44.9 1.43 (**) 3.3 0.14 (.0003)
90 19 2400–<2600 46.9 1.50 (**) 4.5 0.13 (.0003)
98 21 2600–<2800 57.1 1.60 (**) 8.5 0.18 (**)
89 22 2800–<3000 53.0 1.61 (**) 4.9 0.17 (**)
88 24 3000–<3200 58.6 1.65 (**) 9.8 0.20 (**)
91 26 3200–<3400 66.9 1.74 (**) 11.8 0.26 (**)
73 26 3400–<3600 63.3 1.75 (**) 6.6 0.24 (**)
64 28 3600–<3800 78.0 1.80 (**) 10.4 0.25 (**)
40 29 3800–<4000 80.2 1.84 (**) 13.2 0.26 (**)
58 31 4000–4942 75.3 1.84 (**) 10.4 0.26 (**)
N – Number of observations in interval (combines observations from different women).
Cum – cumulative.
Oxy hgb – change in oxygenated hemoglobin, since baseline.
Deoxy hgb – change in deoxygenated hemoglobin, since baseline.
*Increase/decrease (if negative) in oxy or deoxy hgb units per 100 cGy increase over the cumulative dose interval which begins at 0 and ends at the stated Cum dose interval
(ie, 0 < 200 cGy (n = 53), 0–<400 cGy (n = 138), . . ., 0–4942 cGy (n = 1770)), controlling for woman as a random effect.
**p < 0.0001.
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reactions [2]. Our current clinical results suggest relationships
between all three in the setting of acute radiation exposure.
Near linear relationship of OxyHb change and dose
Our previous animal study demonstrated a strong indication for
a dose-dependent phenomenon. We had found that hemoglobin
had a dose-related change after increasing single fraction exposure
(500–5000 cGy) of beta-radiation [9]. Indeed, our current fraction-
ated irradiation findings are consistent with other animal studies
demonstrating a dose-dependent effect on the microvasculature
[15–17]. Interestingly, it appears from this clinical data that there
is a threshold dose (around 600–800 cGy) at which OxyHb’s rela-
tionship to skin dose becomes statistically significant.
Because this clinical study measured the precise skin dose
received using OSLD’s, we had the ability to carefully correlate dose
with skin hemoglobin changes. Between all the sites measured
(SCAR, TB, and MT), there appeared to be largely linear associations
between cumulative dose and oxygenated hemoglobin change. We
demonstrated that between 2 and 5000 cGy, 40% of the change in
oxygenated hemoglobin was accounted for by dose. Although we
tested for other factors such as age, smoking, BMI and chemother-
apy, none helped explain the dose effect; much of the remainder of
variability may be accounted for by inter-patient differences, as it
Fig. 2. Model-predicted change since baseline in oxygenated hemoglobin at combined scar and treatment breast (above), and medial tattoo locations (below), by cumulative
radiation dose (cGy). Model includes 29 women, 1336 observations, (asterisks indicate 95% CI).
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is known that there is a significant degree of skin response varia-
tion among patients [18,19]. The greater variability in the MT site
relative to the combined SCAR and TB model suggests that MT skin
may have a different response. We hypothesize that this difference
is due to the different nature of the sternal skin, which may
undergo significantly more chronic UV sun exposure than either
of the primary breast sites.
There was also a significant but much weaker association of
deoxygenated hemoglobin with cumulative dose. We hypothesize
that this less robust deoxygenated hemoglobin relationship differs
somewhat from our previous animal findings due to the physio-
logic differences between single and fractioned dosing, which
involve lower radiation doses. Lower doses have been suggested
to induce angiogenesis while higher doses have been associated
with vessel destruction and endothelial cell inhibition [20–25].
The dose-dependent nature of OxyHb change seen in our
patients appears to have a temporary decrease in OxyHb over the
first 4 or 5 days. After this time, the change in OxyHb begins to rise
to a near-linear relationship. The initial drop may be explained by
the temporary increase in DeoxyHb seen in our previous animal
study in the first 3 days after single fraction exposure [9]. Explana-
tions for this acute drop in OxyHb (or conversely, increase in Deox-
yHb) may be due to the histamine release and succeeding
inflammatory response that leads to increased vascular leak
[26,27]. Previous studies have demonstrated a relationship
between increasing dose and vascular permeability [15,28,29],
and we believe this phenomenon may explain the brief initial drop
in oxygenated hemoglobin.
Skin reaction and OxyHb relationship to dose
Currently, the development of acute skin reactions during
radiotherapy usually signals a treatment break to allow the tissue
to recover. However, treatment breaks of more than a week during
breast cancer radiotherapy can negatively impact recurrence rate
and overall survival [30,31]. Treatment interruptions in other sen-
sitive areas of the body due to skin reactions, such as head and
neck, have similarly shown decreased locoregional control and
lower overall survival [32]. The ability to identify high-risk areas
or high-risk patients who develop skin reactions earlier and modify
the treatment plan accordingly may circumvent the need for these
Fig. 3. (Above) Mean cumulative dose by skin reaction score, separated by radiation location site (n = 42 women, 2531 observations). Spearman correlations for TB, MT and
SCAR were 0.56861, 0.37381, and 0.58996, respectively (p < 0.0001). (Below) Mean change in oxygenated hemoglobin since baseline by skin reaction score, separated by
radiation location. Spearman correlations for TB, MT and SCAR were 0.64868, 0.54609, and 0.77246, respectively (p < 0.0001).
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detrimental treatment breaks in not only breast but other
radiosensitive areas.
One of the remaining questions regarding radiodermatitis is
whether skin reactions have a predictable relationship with dose
received, and how this could be assessed [33–35]. Although limited
to moist desquamation as the highest form of skin reaction we
observed in our study population, our data indicates that there is
a correlation between degree of skin reaction and increasing dose.
This finding is supported by our previous study of radiodermatitis
in the animal model in which increasing single fractions of beta
radiation led to increased skin reactions and damage to the
microvasculature [9]. Other preclinical studies have supported
the dose dependent effect on the dermis as well [16,17].
Our previous animal study suggested that HSI analysis of hemo-
globin could predict formation of acute skin reactions [9]. Another
spectral imaging technology (DermaScope) has been studied as a
potential objective assessment tool for radiation-induced ery-
thema; however, its correlation with clinical assessments was
not strong [36]. Our preclinical data appears to be confirmed by
the current clinical study.
We have observed that OxyHb response corresponds to the
degree of acute skin injury in TB and SCAR sites. If further vali-
dated, the OxyHb response may prove to be a valuable assessment
tool for the improved skin monitoring of patients receiving both
therapeutic and diagnostic radiologic procedures. Interestingly,
although treatment and scar sites reacted to radiation similarly,
MT differed from the other two sites with a lower skin response.
Similar to the difference in OxyHb-dose model results, we hypoth-
esize that this is due to increased UV sun exposure in MT skin.
Limitations
Despite a significant association, dose was not a perfect predic-
tor of OxyHb. Dose plus patient accounted for about 65% of its vari-
ability, leaving 35% unexplained. The unexplained portion may in
part be due to systematic factors we did not measure, or entirely
to individual patient variability.
The RTOG score agreement had only 68% perfect agreement
between the 2 technicians. We hoped to achieve a better represen-
tation by averaging the two technicians’ scores. This lack of consis-
tency highlights the subjective nature of the scoring system and
the need for an objective gold standard.
Conclusions
Use of HSI hemoglobin analysis may prove useful for the real-
time assessment of patient’s skin response to radiation dose.
Although breast-related skin reactions have significantly decreased
due to modern fractionation schemes, our findings might still be
applicable to other radiosensitive parts of the body, such as head
and neck. We suggest future correlational studies of our breast
model predictions to other areas of the body. Our study demon-
strates strong evidence of radiation dose-response relationship,
however, inter-patient variability remains a challenge, as approxi-
mately 40% of the variability in change in oxygenated hemoglobin
is accounted for by dose, 25% by individual woman, and 35% by
causes we could not model. An upcoming analysis of this patient
cohort will correlate these early adverse reactions and OxyHb
responses to late skin morbidity.
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